Perrigo CO PLC PRGO
We take great care to ensure that the data presented and summarized in this overview for PERRIGO Co plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRGO
View all-
Vanguard Group Inc Valley Forge, PA14.9MShares$413 Million0.01% of portfolio
-
Black Rock Inc. New York, NY13MShares$360 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.85MShares$218 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX6.99MShares$194 Million0.04% of portfolio
-
State Street Corp Boston, MA6.9MShares$191 Million0.01% of portfolio
-
Deprince Race & Zollo Inc Winter Park, FL4.56MShares$127 Million2.38% of portfolio
-
Cooke & Bieler LP3.57MShares$99.2 Million1.0% of portfolio
-
Thompson Siegel & Walmsley LLC2.85MShares$79 Million1.14% of portfolio
-
Ion Asset Management Ltd. George Town, Grand Cayman, E92.82MShares$78.3 Million4.31% of portfolio
-
Neuberger Berman Group LLC New York, NY2.8MShares$77.7 Million0.06% of portfolio
Latest Institutional Activity in PRGO
Top Purchases
Top Sells
About PRGO
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Transactions at PRGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 10
2025
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Open market or private sale
|
Direct |
7,800
-18.81%
|
$210,600
$27.44 P/Share
|
Mar 07
2025
|
Patrick Lockwood Taylor CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,925
-9.59%
|
$159,975
$27.76 P/Share
|
Mar 07
2025
|
Patrick Lockwood Taylor CEO |
BUY
Grant, award, or other acquisition
|
Direct |
16,389
+20.96%
|
$442,503
$27.76 P/Share
|
Mar 07
2025
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,511
-15.43%
|
$175,797
$27.76 P/Share
|
Mar 07
2025
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,738
+38.79%
|
$721,926
$27.76 P/Share
|
Mar 07
2025
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,777
-8.94%
|
$209,979
$27.76 P/Share
|
Mar 07
2025
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+5.16%
|
$58,401
$27.76 P/Share
|
Mar 07
2025
|
Robert Willis EVP & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
12,762
+22.39%
|
$344,574
$27.76 P/Share
|
Mar 07
2025
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,110
-7.16%
|
$164,970
$27.76 P/Share
|
Mar 07
2025
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,941
+6.73%
|
$79,407
$27.76 P/Share
|
Mar 07
2025
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
17,355
+28.74%
|
$468,585
$27.76 P/Share
|
Mar 06
2025
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,271
-3.13%
|
$35,588
$28.68 P/Share
|
Mar 06
2025
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,870
+10.72%
|
$136,360
$28.68 P/Share
|
Mar 06
2025
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
917
-2.27%
|
$25,676
$28.68 P/Share
|
Mar 06
2025
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+4.17%
|
$49,252
$28.68 P/Share
|
Mar 06
2025
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
693
-1.64%
|
$19,404
$28.68 P/Share
|
Mar 06
2025
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+5.17%
|
$64,400
$28.68 P/Share
|
Mar 05
2025
|
Julia M Brown Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,664
-48.02%
|
$77,256
$29.47 P/Share
|
Mar 05
2025
|
Julia M Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,548
+50.0%
|
$160,892
$29.47 P/Share
|
Dec 09
2024
|
Jeffrey B Kindler Director |
SELL
Open market or private sale
|
Direct |
17,598
-76.49%
|
$492,744
$28.27 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 138K shares |
---|---|
Grant, award, or other acquisition | 85.1K shares |
Open market or private purchase | 1K shares |
Payment of exercise price or tax liability | 88.7K shares |
---|---|
Open market or private sale | 82.3K shares |